Solvay has teamed up with French start-up Ostium in a joint project designed to enable the mechanical recycling of end-of-life single-use surgical instruments molded in glass-fiber reinforced Ixef® polyarylamide (PARA) from Solvay’s portfolio of specialty polymers.
The initiative is the first for valuable polymers to be recycled and upcycled from used healthcare devices, proving that the medical safety provided by high-performance polymers such as Solvay’s Ixef® PARA in single-use surgical instruments, can be reconciled with the need for greater sustainability and resource efficiency.
“Our customers in the healthcare industry must meet strict regulatory demands, while at the same time striving to minimize the carbon footprint of their products and support the reduction of hospitals and clinics’ end-of-life waste,” says Claire Guerrero, Global Marketing Manager Sustainability at Solvay. “We identified a gap between these challenges, which prompted us to forge this unique collaboration for developing a breakthrough recycling process for used surgical instruments that are commonly disposed of by incineration rather than reclaiming their high material value. By controlling every step in the loop from the original Ixef® PARA to the upcycled PARA compound, we will be able to ensure its high quality, purity, and performance for demanding downstream applications and can make a significant contribution to a more sustainable polymer economy.”
Ostium Group, a French start-up specializing in the design and manufacture of instruments for hip, knee, shoulder, and trauma orthopedic surgery, will supply hospitals with new custom surgical kits made with Ixef® PARA and collect the contaminated instruments after use. This will also promote the replacement of metal surgical instruments with lightweight polymer designs and help medical facilities reduce their time and cost for sterilization, and disposal as well as lower their carbon footprint.
The partnership with a regionally recognized leader in the treatment and recycling of waste from healthcare activities with infectious risks, was key to developing a dedicated mechanical process to clean, sort, and grind the collected material, delivering high-quality polymer feedstock that can be used in the production of new polymers. In this way, end-of-life surgical instruments can become part of a circular ecosystem that prevents the loss of valuable material and reduces the consumption of fossil resources.
Finally, Solvay is evaluating upcycling options and how to integrate back this recycled feedstock into new high-performance PARA compounds. Initial trials have shown that the recycle-based PARA compound provides a very high level of performance, with up to 85% of flexural properties and no loss in excellent surface appearance when compared with the virgin grade, with the additional advantage of a lower carbon footprint.
In view of regulations in place in the healthcare market with constraints on the use of recycled materials, Solvay is targeting open-loop downstream solutions in which the recycled material will find a second life in high-end markets such as automotive and sports and leisure equipment.
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has introduced several new measures to make it easier to run clinical trials in the country, marking the first time in 20 years the regulatory body has made such an overhaul.
Diabetes drugmaker Novo Nordisk is partnering with Dewpoint Therapeutics in a deal aimed at uncovering new treatments for insulin resistance by targeting cellular droplets known as biomolecular condensates. Dewpoint will receive $55 million upfront from Novo, which plans to develop small molecule drugs against targets discovered using Dewpoint’s technology.
Sanofi has secured approval for Dupixent (dupilumab) from the European Commission (EC) to treat severe atopic dermatitis in children aged six months to five years, who are systemic therapy candidates, in the European Union (EU). This approval makes Dupixent the first and only medicine available in the US and Europe for the treatment of such young children.